Inhibrx Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Net Income	-164.63	-154.96	-115.33
Depreciation & Amortization	1.26	1.19	1.23
Loss (Gain) From Sale of Assets	0	0	0.02
Loss (Gain) on Equity Investments	1.63	1.63	-
Stock-Based Compensation	21.04	20.69	17.79
Other Operating Activities	0.17	0.13	1.62
Change in Accounts Receivable	-	-0.54	0.13
Change in Accounts Payable	2.47	3.45	-0.38
Change in Unearned Revenue	-	-	-1.1
Change in Other Net Operating Assets	-4.33	-0.61	5.21
Operating Cash Flow	-142.38	-129.01	-90.81
Capital Expenditures	-5.69	-4.59	-0.69
Investing Cash Flow	-5.69	-4.59	-0.69
Other Financing Activities	148.07	133.6	91.5
Financing Cash Flow	148.07	133.6	91.5
Free Cash Flow	-148.07	-133.6	-91.5
Free Cash Flow Margin	-9061.87%	-8176.25%	-6957.95%
Cash Income Tax Paid	0	0	0
Levered Free Cash Flow	-	-73.49	-
Unlevered Free Cash Flow	-	-73.49	-
Change in Net Working Capital	-	-4.69	-

Source: S&P Capital IQ. Standard template.